Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 21;7(2):00954-2020.
doi: 10.1183/23120541.00954-2020. eCollection 2021 Apr.

Microparticles in COVID-19 as a link between lung injury extension and thrombosis

Olivier Morel  1   2 , Benjamin Marchandot  1 , Laurence Jesel  1   2 , Laurent Sattler  3 , Antonin Trimaille  1 , Anais Curtiaud  1 , Mickael Ohana  4 , Samira Fafi-Kremer  5 , Valerie Schini-Kerth  2 , Lelia Grunebaum  3 , Jean-Marie Freyssinet  3
Affiliations

Microparticles in COVID-19 as a link between lung injury extension and thrombosis

Olivier Morel et al. ERJ Open Res. .

Abstract

Procoagulant microparticles are associated with the extent of lung injuries in #COVID19 and pulmonary thrombosis https://bit.ly/3eX2LPc.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: O. Morel has nothing to disclose. Conflict of interest: B. Marchandot has nothing to disclose. Conflict of interest: L. Jesel has nothing to disclose. Conflict of interest: L. Sattler has nothing to disclose. Conflict of interest: A. Trimaille has nothing to disclose. Conflict of interest: A. Curtiaud has nothing to disclose. Conflict of interest: M. Ohana has nothing to disclose. Conflict of interest: S. Fafi-Kremer has nothing to disclose. Conflict of interest: V. Schini-Kerth has nothing to disclose. Conflict of interest: L. Grunebaum has nothing to disclose. Conflict of interest: J-M. Freyssinet reports other (royalties) from HYPHEN BioMed, during the conduct of the study; In addition, Dr. Freyssinet has a patent WO1996003655A1 with royalties paid to HYPHEN BioMed and Patent WO1996003655A1 expired several years ago, in 2013–2014 as far as it can be remembered, when giving up paying for yearly fees no longer covered by royalties from HYPHEN BioMed for their Zymuphen MP-activity kits. For instance, patent fee for 2012 was 1902.83 EUR for France and Germany only, not including Japan and US rights. Last royalties, over 36 months (3 years) amounted to 5153 EUR, submitted to 16% taxes paid to the French tax system.

Figures

FIGURE 1
FIGURE 1
a, b) Pro-inflammatory cytokines (monocyte chemoattractant protein-1 (MCP-1) and interleukin (IL)-6) and c, d) cyto-adhesins (intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1)) levels in the study population. e) Procoagulant microparticles (MPs) levels in the study population. f) Procoagulant MPs levels in COVID-19 patients stratified by concomitant in-hospital acute pulmonary embolism (APE). g) Procoagulant MPs levels in COVID-19 patients stratified by lung injury severity (critical >50%) assessed by computed tomography. Boxes indicate median and 25–75th (interquartile) range. Bars indicate minimum and maximum values. Comparisons between groups were made using nonparametric tests. LA: lupus anticoagulant; PhtdSerEq: phosphatidylserine equivalent.
See this image and copyright information in PMC

References

    1. Ackermann M, Verleden SE, Kuehnel M, et al. . Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–128. doi:10.1056/NEJMoa2015432 - DOI - PMC - PubMed
    1. Nieri D, Neri T, Petrini S, et al. . Cell-derived microparticles and the lung. Eur Respir Rev 2016; 25: 266–277. doi:10.1183/16000617.0009-2016 - DOI - PMC - PubMed
    1. Rautou PE, Vion AC, Amabile N, et al. . Microparticles, vascular function, and atherothrombosis. Circ Res 2011; 109: 593–606. doi:10.1161/CIRCRESAHA.110.233163 - DOI - PubMed
    1. Aupeix K, Hugel B, Martin T, et al. . The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99: 1546–1554. doi:10.1172/JCI119317 - DOI - PMC - PubMed
    1. Abbas M, Jesel L, Auger C, et al. . Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity: role of the Ang II/AT1 receptor/NADPH oxidase-mediated activation of MAPKs and PI3-Kinase pathways. Circulation 2017; 135: 280–296. doi:10.1161/CIRCULATIONAHA.116.017513 - DOI - PubMed

LinkOut - more resources